286P Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study
Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Fabio Falcini(Centro di Riferimento Oncologico), Alessandra Ravaioli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Stefano Ferretti(University of Ferrara), Francesco Faccini(University of Genoa), Maria Michiara, Veruska Grossi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Daniella K. Zanoni(University of Parma), C. Tommasi(University of Parma), Paolo Sgargi(University of Parma), Federica Zamagni(Cancer Institute (WIA)), Ò. Serra(University of Parma), Giuliano Carrozzi, Benedetta Pellegrino(University of Parma)
Cited by 1
Related Papers
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271
Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast Cancer
|New England Journal of Medicine|2024|235
Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy
|British Journal of Cancer|1998|140